• Olaparib Workflow for DNA Damage Studies

  2026-09-23

  Build reproducible Olaparib experiments for BRCA-deficient models, DNA damage response assays, and tumor radiosensitization studies. A practical workflow also shows how SmD2-dependent splicing biology can extend PARP inhibitor research into BRCA-wild-type hepatocellular carcinoma models.

• Novobiocin Workflows for Antimicrobial Research

  2026-09-22

  Build reproducible Novobiocin workflows for staphylococcal susceptibility testing, parasite and virus screens, and mechanism-focused cell assays. The guide separates reference-backed findings from practical optimization, helping researchers use this aminocoumarin antibiotic without conflating antibacterial, antiparasitic, antiviral, or Hsp90-related readouts.

• Midecamycin: From MIC to PK/PD Assay Design

  2026-09-22

  Midecamycin is an acetoxy-substituted macrolide antibiotic whose ribosomal mechanism and strain-dependent MIC profile make it valuable for exposure-aware antibacterial research. This guide connects assay design with PK/PD reasoning while distinguishing direct evidence from translational interpretation.

• OTUD3–SLC7A11 Signaling in Sunitinib Resistance

  2026-09-21

  A 2025 Cancer Letters study identifies OTUD3 as a deubiquitinase that stabilizes SLC7A11, preserves cystine utilization, and suppresses sunitinib-induced ferroptosis in clear cell renal cell carcinoma. The work connects protein stability with lipid peroxide control and suggests that measuring oxidative injury alongside OTUD3–SLC7A11 activity may clarify mechanisms of tyrosine kinase inhibitor resistance.

• Glycogen Colorimetric Assay Kit II for Circadian Studies

  2026-09-21

  The Glycogen Colorimetric Assay Kit II enables sensitive, interference-conscious glycogen measurement in exercise and circadian research. This article explains how to use glycogen data to distinguish substrate availability from training adaptation, with practical guidance for high-throughput study design.

• SHC-1 Inhibition and CFTR Surface Trafficking

  2026-09-20

  This 2026 study shows that MAPK/SHC-1-dependent CFTR internalization occurs across airway and intestinal epithelial models, but that pharmacological SHC-1 inhibition increases surface CFTR only in CFBE cells. The work highlights cell-type-specific trafficking biology and demonstrates why changes in CFTR abundance should be interpreted alongside unrelated plasma-membrane markers and functional assays.

• GSK343 EZH2 Inhibitor: Workflow and Applications

  2026-09-19

  GSK343 enables selective, cell-permeable interrogation of EZH2-dependent H3K27me3 repression in cancer and stem-cell models. This practical guide connects compound handling with TERT chromatin assays, proliferation studies, and troubleshooting strategies for reproducible epigenetic research.

• Novobiocin Workflows for Antimicrobial Research

  2026-09-18

  Build more reproducible bacterial susceptibility, antiparasitic, and antiviral experiments with Novobiocin, an aminocoumarin antibiotic that targets DNA gyrase B and may also perturb Hsp90-dependent processes. This guide translates comparative staphylococcal data into practical assay design, solvent controls, concentration selection, and troubleshooting decisions.

• Ferrocenyl Novobiocin Derivatives: Study Insights

  2026-09-18

  The reference study developed ferrocenyl and organic derivatives of the aminocoumarin antibiotic Novobiocin and compared their in vitro activity against Plasmodium falciparum and breast cancer cells. Its matched scaffold strategy indicates that ferrocene incorporation can improve activity in several analogues, while also showing why activity gains must be interpreted in the context of substitution pattern and biological model.

• Streptozotocin Workflows for Diabetes Research

  2026-09-17

  Learn how Streptozotocin and STZ support reproducible β-cell injury, hyperglycemia, and diabetes-model workflows. The article also shows how to connect metabolic disease induction with TBK1-driven microglial pyroptosis assays in painful diabetic neuropathy research.

• Novobiocin Against Equine Piroplasms: Study Insights

  2026-09-17

  The reference study identifies heat shock protein 90 as a therapeutically relevant target in Theileria equi and Babesia caballi and evaluates novobiocin as an experimental anti-piroplasmic agent. Its combination of parasite-growth assays, host-cell selectivity testing, haemolysis measurements, and mouse organ-toxicity assessment provides a useful preclinical framework, while leaving important questions about parasite clearance and clinical translation unresolved.

• GSK343: EZH2 Inhibition Meets TERT Biology

  2026-09-16

  GSK343 is a selective EZH2 inhibitor for dissecting H3K27me3-dependent gene repression in cancer models. This article connects its assay logic to new APEX2–TERT findings while clarifying what can—and cannot—be inferred about telomerase regulation.

• Novobiocin: From Target to Assay Decision

  2026-09-16

  Novobiocin is an aminocoumarin antibiotic whose antibacterial, antiparasitic, antiviral, and Hsp90-related activities require carefully matched assay designs. This guide translates target biology, concentration selection, and derivative-study evidence into practical decisions for reproducible research.

• Aclacinomycin A and the Hidden Logic of rDNA Damage

  2026-09-15

  Aclacinomycin A, or Aclarubicin, is more than a cytotoxic benchmark: its dual topoisomerase activity provides a strategic entry point for studying persistent ribosomal DNA damage, PML-nucleolar responses, apoptosis, and translational resistance mechanisms.

• Topological Stress, rDNA Lesions, and PML Compartments

  2026-09-15

  This study shows that topological stress and RNA polymerase I inhibition generate persistent lesions in ribosomal DNA, leading to PML-nucleolar associations that sequester damaged rDNA from active nucleoli. Its combination of targeted rDNA cleavage, repair-pathway perturbation, and imaging connects unresolved homologous-recombination intermediates with nuclear reorganization and cellular senescence.

8079 records 1/539 page Next 12345 下5页 Last page